Latest & greatest articles for breast cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on breast cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for breast cancer

1. Somatic tumour gene testing for the diagnosis of renal cell carcinoma, hydatidiform moles, granulosa cell ovarian tumour, salivary gland tumours, and secretory carcinoma of the breast

, as requested by a specialist or consultant physician, for the characterisation of MALM2 gene rearrangement. Maximum one test per lifetime Fee: $340 XXXXX-17 Analysis of tumour tissue from a patient with clinical or laboratory evidence, including morphological features, of mammary analogue secretory carcinoma of the salivary gland, as requested by a specialist or consultant physician, for the characterisation of ETV6-NTRK3 gene rearrangement. Maximum one test per lifetime Fee: $340 XXXXX-18 Analysis (...) or mammary analogue secretory carcinoma (MASC) of salivary glands. Fee: $454 each OR In the assessment of malignant salivary gland tumours, identification of: • MALM2 gene status for the diagnosis of mucoepidermoid carcinoma AND/OR • ETV6-NTRK3 gene status for the diagnosis of analogue secretory carcinoma AND/OR • EWSR1 gene status for the diagnosis of hyalinising clear cell carcinoma. Fee: $454 (for each) OR Identification of TFE3 or TFEB gene rearrangement in the assessment of renal cell carcinoma. Fee

2020 Medical Services Advisory Committee

2. Gene Expression Profiling Tests for Early-Stage Invasive Breast Cancer

-expression-profiling-tests-for-early-stage-invasive-breast-cancer March 2020 Ontario Health Technology Assessment Series; Vol. 20: No. 10, pp. 1–234, March 2020 3 ABSTRACT Background Breast cancer is a disease in which cells in the breast grow out of control. They often form a tumour that may be seen on an x-ray or felt as a lump. Gene expression profiling (GEP) tests are intended to help predict the risk of metastasis (spread of the cancer to other parts of the body) and to identify people who will most (...) and the experiences, preferences, and values of people with early-stage invasive breast cancer. BACKGROUND Health Condition Breast cancer is a disease in which cells in the breast grow out of control, eventually forming a tumour. Environmental, lifestyle, and genetic factors influence a person’s risk of developing breast cancer. These risk factors may include obesity, physical inactivity, alcohol consumption, age, hormone replacement therapy, dense breasts, genetic mutation, and a personal and/or family history

2020 Health Quality Ontario

3. Similar Breast Cancer Risk in Women Older Than 65 Years Initiating Glargine, Detemir, and NPH Insulins

Similar Breast Cancer Risk in Women Older Than 65 Years Initiating Glargine, Detemir, and NPH Insulins Similar Breast Cancer Risk in Women Older Than 65 Years Initiating Glargine, Detemir, and NPH Insulins - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes (...) to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Diabetes Care Actions 2020 Feb 19 [Online ahead of print] Similar Breast Cancer Risk in Women Older Than 65 Years Initiating Glargine, Detemir, and NPH Insulins , , , , , , , , , , Affiliations Expand Affiliations 1 Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver

2020 EvidenceUpdates

4. Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221)

Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221) Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221) - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard (...) collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation J Clin Oncol Actions , 38 (8), 804-814 2020 Mar 10 Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221

2020 EvidenceUpdates

5. Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial (Abstract)

Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial The phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway is frequently activated in triple-negative breast cancer (TNBC). The AKT inhibitor capivasertib has shown preclinical activity in TNBC models, and drug sensitivity has been associated with activation of PI3K or AKT and/or deletions of PTEN. The PAKT trial was designed to evaluate the safety (...) and efficacy of adding capivasertib to paclitaxel as first-line therapy for TNBC.This double-blind, placebo-controlled, randomized phase II trial recruited women with untreated metastatic TNBC. A total of 140 patients were randomly assigned (1:1) to paclitaxel 90 mg/m2 (days 1, 8, 15) with either capivasertib (400 mg twice daily) or placebo (days 2-5, 9-12, 16-19) every 28 days until disease progression or unacceptable toxicity. The primary end point was progression-free survival (PFS). Secondary end

2020 EvidenceUpdates

6. CYP2D6 Genotype-Guided Tamoxifen Dosing in Hormone Receptor-Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase II Study (Abstract)

CYP2D6 Genotype-Guided Tamoxifen Dosing in Hormone Receptor-Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase II Study In patients taking tamoxifen, the CYP2D6 genotype causes different exposure of active metabolite endoxifen. The objective of this randomized, open-label, multicenter, phase II study was to prospectively evaluate whether CYP2D6 genotype-guided tamoxifen dosing in patients with hormone receptor-positive metastatic breast cancer could have an impact (...) in the RD arm (median, 89.2 nM v 51.1 nM; P < .0001) and were also higher compared with wt/wt patients (72.0 nM; P = .045). No significant difference in Z-endoxifen concentrations was observed between patients with disease progression and those who were progression free at 6 months (P = .43).In patients with CYP2D6-variant alleles, increasing tamoxifen dosing did not achieve a higher PFS rate at 6 months. The CYP2D6 genotype solely cannot explain individual variability in the efficacy of tamoxifen.

2020 EvidenceUpdates

7. Risks and Benefits of HRT before and after a Breast Cancer Diagnosis

Risks and Benefits of HRT before and after a Breast Cancer Diagnosis Risks and Benefits of HRT before and after a Breast Cancer Diagnosis | British Menopause Society Search for: Summary consensus statement Risks and Benefits of HRT before and after a Breast Cancer Diagnosis Risks and Benefits of HRT before and after a Breast Cancer Diagnosis 2018-11-28T11:58:36+01:00 Summary In women with a low underlying risk of breast cancer (i.e. most of the population): The benefits of HRT in the short-term (...) (up to 5 years’ use) for symptom relief will exceed potential harm The risk of breast cancer diagnosis associated with HRT is equivalent to, or less that of other lifestyle risk factors for breast cancer Communicating risk in terms of absolute excess risk with framing, minimizes bias and misinterpretation The potential risk of breast cancer diagnosis associated with unopposed or combined HRT should not be discussed in isolation of its other short and long-term benefits and risks In women at high

2020 British Menopause Society

8. Trastuzumab (Trazimera) - Breast Cancer or Gastric Cancer

Trastuzumab (Trazimera) - Breast Cancer or Gastric Cancer Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved after September 1

2020 Health Canada - Drug and Health Product Register

9. Neratinib maleate (Nerlynx) - adjuvant treatment of women with early-stage hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-overexpressed/amplified breast cancer

Neratinib maleate (Nerlynx) - adjuvant treatment of women with early-stage hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-overexpressed/amplified breast cancer Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related

2020 Health Canada - Drug and Health Product Register

10. Talazoparib (Talzenna) - the treatment of adult patients with a deleterious or suspected deleterious germline breast cancer susceptibility gene (BRCA)-mutated human epidermal growth factor receptor 2 (HER2)-negative locally advanced (not amenable to curat

Talazoparib (Talzenna) - the treatment of adult patients with a deleterious or suspected deleterious germline breast cancer susceptibility gene (BRCA)-mutated human epidermal growth factor receptor 2 (HER2)-negative locally advanced (not amenable to curat Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact

2020 Health Canada - Drug and Health Product Register

11. Fam-trastuzumab deruxtecan-nxki (Enhertu) - metastatic breast cancer

Fam-trastuzumab deruxtecan-nxki (Enhertu) - metastatic breast cancer Drug Approval Package: ENHERTU ENHERTU " /> U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: ENHERTU Company: Daiichi Sankyo, Inc. Application Number: 761139 Approval Date: 12/20/2019 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF) (PDF) (PDF

2020 FDA - Drug Approval Package

12. Estrogen and Progesterone Receptor Testing in Breast Cancer Guideline Update

% to 10% staining. Similar principles apply to PgR testing, which is used primarily for prognostic purposes in the setting of an ER-positive cancer. Testing of ductal carcinoma in situ (DCIS) for ER is recommended to determine potential benefit of endocrine therapies to reduce risk of future breast cancer, while testing DCIS for PgR is considered optional. Additional information can be found at www.asco.org/breast-cancer-guidelines. (ArchPatholLabMed.doi:10.5858/arpa.2019-0904-SA) INTRODUCTION F irst (...) tested for hormone receptors? Target Population Patients with breast cancer. Target Audience Medical oncologists, pathologists, surgeons, radiation oncologists, and patients and their caregivers. Methods A multidisciplinary Expert Panel was convened to update the clinical practice guideline recommendations based on a systematic review of the medical literature. Recommendations Recommendation 1.1: Optimal algorithm for ER/progesterone receptor testing. Samples with 1% to 100% of tumor nuclei positive

2020 College of American Pathologists

13. Estrogen and Progesterone Receptor Testing in Breast Cancer

with breast cancer. Target Audience Medical oncologists, pathologists, surgeons, radiation oncologists, and patients and their caregivers. Methods A multidisciplinary Expert Panel was convened to update the clinical practice guideline recommendations based on a systematic review of the medical literature. Recommendations Recommendation 1.1 : Optimal algorithm for ER/progesterone receptor testing . Samples with 1% to 100% of tumor nuclei positive for ER or progesterone receptor (PgR) are interpreted (...) are ready to be incorporated into routine testing for ER and PgR (Clinical Question 3). All the recommendations apply to patients with invasive breast cancer; however, recommendations on hormone receptor testing in ductal carcinoma in situ (DCIS) are also offered (Clinical Question 4). GUIDELINE QUESTIONS Section: This update specifically addresses four clinical questions raised after the publication of the 2010 guideline: What are the optimum quality assurance (QA), tissue handling, scoring system

2020 American Society of Clinical Oncology Guidelines

14. Cancer Screening: Interventions Engaging Community Health Workers – Breast Cancer

neoplasms/ or colonic neoplasms/ or rectal neoplasms/) and (di or pc).fs. 3. ((adenoma* or neoplasia or cancer* or neoplasm* or tumo?r* or carcinoma* or adenocarcinoma*) and (breast or cervical or cervix or colon or colorectal or crc)).ti,ab. 4. 2 or 3 5. 1 and 4 6. colonography, computed tomographic/ or colonoscopy/ or endoscopy, gastrointestinal/ or sigmoidoscopy/ or ((occult blood.ti,ab. or occult blood/) and (feces/ or (faeces or fecal or faecal or colorectal).ti,ab.)) or (enema/ and barium sulfate (...) or 42 CommGuideCancerMCIPsycINFO 1. (mass screening or multiphasic screening or screen or screened or screening or "early detection of cancer").mp. 2. ((neoplasm* or ductal breast carcinoma* or "hereditary breast and ovarian cancer syndrome") and (diagnosis or prevention)).mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures] 3. ((adenoma* or neoplasia or cancer* or neoplasm* or tumo?r* or carcinoma* or adenocarcinoma*) and (breast or cervical

2020 Community Preventive Services Task Force

15. OWise mobile app and website for supporting women with breast cancer - Innovative Medical Technology Overview

OWise mobile app and website for supporting women with breast cancer - Innovative Medical Technology Overview IMTO | 1 IMTO 02-20 January 2020 OWise mobile app and website for supporting women with breast cancer Innovative Medical Technology Overview Key points ? OWise Breast Cancer is an app and website that offer a suite of tailored information and tools to support women with breast cancer. ? Included in the OWise app is information on disease pathology and care pathways, tailored questions (...) in London is comparing outcomes in patients with breast cancer who receive the OWise app plus standard information, with patients who receive standard information alone 9, 10 . The effect of the OWise app on patient activation (a measure of patients’ knowledge of their disease and confidence in managing their care), health-related quality of life (HRQoL), health status, psychological distress, NHS resource utilisation and healthcare costs will be assessed. The study is expected to be completed in 2021

2020 SHTG Advice Statements

16. Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer

this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop. Wh Why the committee made these recommendations y the committee made these recommendations As agreed during the technical engagement stage, this appraisal focuses on the population who have breast cancer that is resistant to endocrine therapy. This includes people whose disease has progressed up to 12 months after (...) -positive, HER2-negative, advanced breast cancer (TA619) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 7 of 20has a convenient daily oral administration and a favourable side-effect profile compared with alternative treatment options. They also highlighted the importance of people living for longer without their disease progressing, therefore in better health. Second-line treatment for hormone receptor- positive

2020 National Institute for Health and Clinical Excellence - Technology Appraisals

17. Risk Factors and Outcomes During a First Acute Myocardial Infarction in Breast Cancer Survivors Compared with Females without Breast Cancer

revascularization. In-hospital mortality was lower in breast cancer survivors (7.1%) compared with those without (7.9%, P < .001), findings that persisted after risk adjustment (odds ratio 0.89; 95% CI, 0.82-0.94). Conclusions: Breast cancer survivors had a first acute myocardial infarction at an older age and had small but favorable differences in cardiovascular disease risk factors and outcomes compared with women without breast cancer. The favorable impact of health education, preventative medical care (...) , greater motivation for a healthier lifestyle, and participation in cancer survivorship programs on these seemingly paradoxical findings in breast cancer survivors should be further explored. Keywords: Acute myocardial infarction; Breast cancer; Cardiovascular disease; Outcomes; Risk factors. Copyright © 2019 Elsevier Inc. All rights reserved. Similar articles S Khera et al. J Am Coll Cardiol 66 (18), 1961-1972. 2015. PMID 26515998. Younger women are less likely to receive revascularization for STEMI

2020 EvidenceUpdates

18. Principles of shared follow-up care for early breast cancer

Principles of shared follow-up care for early breast cancer canceraustralia.gov.au Principles of shared follow-up care for early breast cancer SHARED FOLLOW-UP AND SURVIVORSHIP CARE FOR EARLY BREAST CANCER Cancer Australia’s seven Principles of shared follow-up care for early breast cancer are designed to underpin the delivery of shared follow-up and survivorship care for early breast cancer by health professionals and health services. Person-centred care The individual and their whole person (...) of care and integration across treatment modalities, providers and health settings. Care is informed and improved by data Improvements in shared care are data-driven. The collection and utilisation of key cancer data, including consumer experience and outcome data, supports the delivery of holistic patient care and continuous improvement in care. Support for living well Individuals are supported to make positive lifestyle choices which promote health, reduce risk of disease and prevent distress

2020 Cancer Australia

19. Shared follow-up care for early breast cancer: summary of evidence

on Australia’s health system and resources. Shared care leverages the skills and expertise of the specialist and primary care workforce to support the delivery of high quality, safe and sustainable follow-up and survivorship care. Breast cancer will affect 1 in 7 people in Australia in their lifetime. It is estimated that 19,535 people will be diagnosed with the disease in Australia in 2019 (19,371 women and 164 men). 1 Australians experience some of the highest cancer survival rates in the world. 2,3 Breast (...) care within a shared care model, and factors influencing adherence cost-efficiency of shared follow-up care compared with specialist-led models of follow-up care the evidence relating to national and international shared follow-up cancer care. * Early breast cancer is defined as tumours of not more than five centimetres diameter, with either impalpable or palpable but not fixed lymph nodes and with no evidence of distant metastases. a Women with DCIS are considered suitable to receive shared follow

2020 Cancer Australia

20. Role of intermittent pneumatic compression in the treatment of breast cancer-related lymphoedema: a randomized controlled trial

Role of intermittent pneumatic compression in the treatment of breast cancer-related lymphoedema: a randomized controlled trial Role of Intermittent Pneumatic Compression in the Treatment of Breast Cancer-Related Lymphoedema: A Randomized Controlled Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other advanced features (...) a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Clin Rehabil Actions , 269215519888792 2019 Dec 4 [Online ahead of print] Role of Intermittent Pneumatic Compression in the Treatment of Breast Cancer-Related Lymphoedema: A Randomized Controlled Trial , , , , , , Affiliations Expand Affiliations 1 Department of Physical Medicine

2020 EvidenceUpdates